Annual Working Capital
$344.97 M
-$124.58 M-26.53%
December 31, 2023
Summary
- As of February 7, 2025, RXRX annual working capital is $344.97 million, with the most recent change of -$124.58 million (-26.53%) on December 31, 2023.
- During the last 3 years, RXRX annual working capital has risen by +$101.63 million (+41.76%).
- RXRX annual working capital is now -29.32% below its all-time high of $488.06 million, reached on December 31, 2021.
Performance
RXRX Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$365.28 M
-$71.01 M-16.28%
September 30, 2024
Summary
- As of February 7, 2025, RXRX quarterly working capital is $365.28 million, with the most recent change of -$71.01 million (-16.28%) on September 30, 2024.
- Over the past year, RXRX quarterly working capital has increased by +$95.59 million (+35.44%).
- RXRX quarterly working capital is now -40.90% below its all-time high of $618.10 million, reached on June 30, 2021.
Performance
RXRX Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
RXRX Working Capital Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -26.5% | +35.4% |
| 3 y3 years | +41.8% | -22.2% |
| 5 y5 years | +394.8% | -22.2% |
RXRX Working Capital Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -29.3% | at low | -31.6% | +35.4% |
| 5 y | 5-year | -29.3% | +394.8% | -40.9% | +87.4% |
| alltime | all time | -29.3% | +394.8% | -40.9% | +87.4% |
Recursion Pharmaceuticals Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $365.28 M(-16.3%) |
| Jun 2024 | - | $436.29 M(+61.8%) |
| Mar 2024 | - | $269.69 M(-21.8%) |
| Dec 2023 | $344.97 M(-26.5%) | $344.97 M(+9.0%) |
| Sep 2023 | - | $316.40 M(-0.2%) |
| Jun 2023 | - | $317.06 M(-20.7%) |
| Mar 2023 | - | $399.98 M(-14.8%) |
| Dec 2022 | $469.55 M | $469.55 M(+17.8%) |
| Sep 2022 | - | $398.58 M(-11.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $449.34 M(-15.8%) |
| Mar 2022 | - | $533.75 M(+9.4%) |
| Dec 2021 | $488.06 M(+100.6%) | $488.06 M(-12.5%) |
| Sep 2021 | - | $557.93 M(-9.7%) |
| Jun 2021 | - | $618.10 M(+217.0%) |
| Mar 2021 | - | $194.97 M(-19.9%) |
| Dec 2020 | $243.34 M(+249.1%) | - |
| Dec 2020 | - | $243.34 M |
| Dec 2019 | $69.71 M | - |
FAQ
- What is Recursion Pharmaceuticals annual working capital?
- What is the all time high annual working capital for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual working capital year-on-year change?
- What is Recursion Pharmaceuticals quarterly working capital?
- What is the all time high quarterly working capital for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly working capital year-on-year change?
What is Recursion Pharmaceuticals annual working capital?
The current annual working capital of RXRX is $344.97 M
What is the all time high annual working capital for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual working capital is $488.06 M
What is Recursion Pharmaceuticals annual working capital year-on-year change?
Over the past year, RXRX annual working capital has changed by -$124.58 M (-26.53%)
What is Recursion Pharmaceuticals quarterly working capital?
The current quarterly working capital of RXRX is $365.28 M
What is the all time high quarterly working capital for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly working capital is $618.10 M
What is Recursion Pharmaceuticals quarterly working capital year-on-year change?
Over the past year, RXRX quarterly working capital has changed by +$95.59 M (+35.44%)